Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.

Annals of surgical oncology - 1 Oct 2017

Gamble Charlotte, Havrilesky Laura J, Myers Evan R, Chino Junzo P, Hollenbeck Scott, Plichta Jennifer K, Kelly Marcom P, Shelley Hwang E, Kauff Noah D, Greenup Rachel A

Abstract excerpt

BACKGROUND: The appropriate management of breast cancer risk in BRCA mutation carriers following ovarian cancer diagnosis remains unclear. We sought to determine the survival benefit and cost effectiveness of risk-reducing mastectomy (RRM) among women with BRCA1/2 mutations following stage II-IV ovarian cancer. DESIGN: We constructed a decision model from a third-party payer perspective to compare annual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Early Detection of Cancer

Share to Mastectomy

Share to Monte Carlo Method

Share to Quality-Adjusted Life Years

Share to Risk Reduction Behavior

Source

Open in PubMed Open full text

Identifiers

PMID: 28699130
DOI: 10.1245/s10434-017-5995-z
PMCID: PMC5990891

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.PMID 28699130Read ↗

Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?Semantic proximity Read ↗

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Semantic proximity Read ↗

Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.Semantic proximity Read ↗

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.Semantic proximity Read ↗

When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.Semantic proximity Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

A discrete event simulation to evaluate the cost effectiveness of germline <i>BRCA1</i> and <i>BRCA2</i> testing in UK women with ovarian cancerSemantic proximity Read ↗

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.Semantic proximity Read ↗

Online tool to guide decisions for BRCA1/2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.